Millennium Expects Velcade Accelerated Approval In ’03: Is Phase II Enough?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Millennium is confident that its multiple myeloma treatment Velcade (bortezomib, formerly PS-341) will receive accelerated approval on the basis of Phase II trials in its Jan. 21 NDA submission.